Efficacy and tolerability of brivaracetam in the treatment of epilepsy: literature review and own experience

Cover Page

Cite item

Full Text

About the authors

O. A. Pylaeva

Svt. Luka’s Institute of Child Neurology and Epilepsy;
Svt. Luka’s Institute of Child and Adult Neurology

Author for correspondence.
Email: fake@neicon.ru

5 Nagornaya St., Troitsk, Moscow 108841; 

9 Akad. Anokhina St., 119579 Moscow

Russian Federation

K. Yu. Mukhin

Svt. Luka’s Institute of Child Neurology and Epilepsy;
Svt. Luka’s Institute of Child and Adult Neurology

Email: center@epileptologist.ru

5 Nagornaya St., Troitsk, Moscow 108841; 

9 Akad. Anokhina St., 119579 Moscow

Russian Federation

References

  1. Karlov V.A., Vlasov P.N., Zhidkova I.A. et al. Brivaracetam in the treatment of epilepsy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2017;117(9):55–62. (In Russ.).
  2. Medication package insert for Briviact®. Available at: http://grls.rosminzdrav.ru/Grls_View_ v2.aspx?routingGuid=b8cf75da-e6454d3d-aa29-a64a9e35cd6f&t. (In Russ.).
  3. Andres E., Kerling F., Hamer H., Winterholler M. Behavioural changes in patients with intellectual disability treated with brivaracetam. Acta Neurol Scand 2018;138(3):195–202. PMID: 29658982. doi: 10.1111/ane.12943.
  4. Ben-Menachem E., Mameniškienė R., Quarato P.P. et al. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology 2016;87(3):314–23. PMID: 27335114. doi: 10.1212/WNL.0000000000002864.
  5. Biton V., Berkovic S.F., Abou-Khalil B. et al. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia 2014;55(1):57–66. PMID: 24446953. doi: 10.1111/epi.12433.
  6. Brodie M.J., Fakhoury T., McDonough B. et al. Brivaracetam-induced elevation of carbamazepine epoxide levels: A posthoc analysis from the clinical development program. Epilepsy Res 2018;145:55–62. doi: 10.1016/j.eplepsyres.2018.06.002.
  7. Diaz A., Elmoufti S., Schiemann J., Whitesides J. Efficacy and safety of adjunctive brivaracetam for partial-onset (focal) seizures (POS) in patients with Type IC seizures at baseline: Pooled results from three fixed-dose, randomized, doubleblind, placebo-controlled, phase III studies. Neurology 2016;86(16 Suppl). Annual meeting of the 68th American Academy of Neurology (AAN), April 15–21, 2016, Vancouver, Canada. Abstr. P2.042.
  8. French J.A., Costantini C., Brodsky A. et al. Adjunctive Brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology 2010;75(6):519–25. DOI: 10.1212/ WNL.0b013e3181ec7f7f.
  9. Hirsch M., Hintz M., Specht A., SchulzeBonhage A. Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: a monocenter retrospective outcome analysis. Seizure 2018;61:98–103. PMID: 30118932. doi: 10.1016/j.seizure.2018.07.017.
  10. Klein P., Schiemann J., Sperling M.R. et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive Brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia 2015;56(12):1890–8. PMID: 26471380. DOI: 10.1111/ epi.13212.
  11. Klein P., Diaz A., Gasalla T., Whitesides J. A review of the pharmacology and clinical efficacy of brivaracetam. Clin Pharmacol 2018;10:1–22. PMID: 29403319. doi: 10.2147/CPAA.S114072.
  12. Kwan P., Trinka E., van Paesschen W. et al. Adjunctive Brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia 2014;55(1):38–46. PMID: 24116853. DOI: 10.1111/ epi.12391.
  13. Kwan P., Brodie M.J. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000;9(7):464–8. PMID: 11034869. doi: 10.1053/seiz.2000.0442.
  14. Kwan P., Brodie M.J. Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother 2006;6(3):397–406. PMID: 16533143. doi: 10.1586/14737175.6.3.397.
  15. Ryvlin P., Werhahn K.J., Blaszczyk B. et al. Adjunctive Brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia 2014;55(1):47–56. PMID: 24256083. doi: 10.1111/epi.12432.
  16. Sanon N.T., Gagné J., Wolf D.C. et al. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model. Epilepsy Behav 2018;79:117–25. PMID: 29287214. doi: 10.1016/j.yebeh.2017.11.019.
  17. Shoenmarker N., Wade J.R., Stockis A. Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years. Eur J Clin Pharmacol 2017;73(6):727–33. PMID: 28280887. doi: 10.1007/s00228-017-2230-6.
  18. Stephen L.J., Brodie M.J. Brivaracetam: a novel antiepileptic drug for focal-onset seizures. Ther Adv Neurol Disord 2017;11:1756285617742081. PMID: 29399049. doi: 10.1177/1756285617742081.
  19. Strzelczyk A., Steinig I., Klein K.M. et al. Brivaracetam for add-on treatment in focal epilepsy. Nervenarzt 2016;87(10):1086–93. PMID: 27389600. doi: 10.1007/s00115016-0163-4.
  20. Strzelczyk A., Kay L., Bauer S. et al. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia 2018;59(8):1549–56. PMID: 29943451. DOI: 10.1111/ epi.14476.
  21. Strzelczyk A., Klein K.M., Willems L.M. et al. Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clin Pharmacol 2016;9(5):637–45. PMID: 26891946. doi: 10.1586/17512433.2016.1156529.
  22. Toledo M., Whitesides J., Schiemann J. et al. Safety, tolerability, and seizure control during long-term treatment with adjunctive Brivaracetam for partial-onset seizures. Epilepsia 2016;57(7):1139–51. PMID: 27265725. doi: 10.1111/epi.13416.
  23. Van Paesschen W., Hirsch E., Johnson M. et al. Efficacy and tolerability of adjunctive Brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia 2013;54(1):89–97. PMID: 22813235. doi: 10.1111/j.1528-1167.2012.03598.x.
  24. Willems L.M., Bertsche A., Bösebeck F. et al. Retention, and tolerability of brivaracetam in patients with epileptic encephalopathies: a multicenter cohort study from Germany. Front Neurol 201823;9:569. PMID: 30083127. doi: 10.3389/fneur.2018.00569.
  25. Wood M.D., Sands Z.A., Vandenplas C., Gillard M. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein. Epilepsia 2018;59(9):e147–51. PMID: 30144048. DOI: 10.1111/ epi.14532.
  26. Xiao X., Ouyang Y., Song Z., Zheng W. Progress in synaptic mechanism in epileptogenesis. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2018;43(1):90–4. PMID: 30154297. DOI: 10.11817/j. issn.1672-7347.2018.01.014.
  27. Zahnert F., Krause K., Immisch I. et al. Brivaracetam in the treatment of patients with epilepsy-first clinical experiences. Front Neurol 2018;6;9:38. PMID: 29467714. DOI: 10.3389/ fneur.2018.00038.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 22926 от  12.01.2006.